MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
Returns on capital
MBX Biosciences, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.6%
avg 14.7%
ROIC
-26.5%
avg -39.3%
ROA
-22.6%
avg -35.6%
Analysis
ROA is currently the strongest return metric at -22.6% versus its period average of -35.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Salomon Azoulay | Chief Medical Officer | USD 734.94K | 68 | 14.03K | 0.04% |
John W. Smither | Chief Financial Officer | USD 642K | 73 | 28.00K | 0.08% |
Steven L. Hoerter | Executive Chairperson, CEO & President | USD 40.48K | 55 | 78.05K | 0.23% |
Jeffrey Held | Chief Legal Officer | — | 57 | — | — |
Mark Hope | Chief Regulatory & Quality Officer | — | — | — | — |
Andreas Moraitis | Senior Vice President of Clinical Development | — | — | — | — |
Mark R. Soued | Chief Commercial Officer | — | — | — | — |
Karen Basbaum | Chief Business Officer | — | — | — | — |
Michelle Graham | Chief Human Resources Officer | — | 59 | — | — |
Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls | — | — | — | — |
Michael A. Dorato DABT | Sr. Vice President of Discovery & Non-Clinical Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$525,662.70
Sells
7
$3.02M
Net Transaction Value
−$2.50M
Net selling
Most Active
Azoulay Salomon
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 10, 26Nov 10, 2026 | Hoerter Steven L. Direct | Sell | $268.2K$268,234.26 |
| Nov 4, 26Nov 4, 2026 | Azoulay Salomon Direct | Sell | $20.1K$20,127.08 |
| Aug 4, 26Aug 4, 2026 | Azoulay Salomon Direct | Sell | $24.3K$24,334.90 |
| May 8, 26May 8, 2026 | Azoulay Salomon Direct | Sell | $2.1M$2,110,900.00 |
| May 8, 26May 8, 2026 | Azoulay Salomon Direct | Sell | $574.6K$574,614.90 |
| May 6, 26May 6, 2026 | Hawryluk P. Kent Direct | Sell | $17.9K$17,930.78 |
| May 6, 26May 6, 2026 | Azoulay Salomon Direct | Sell | $6.8K$6,823.74 |
| Mar 13, 26Mar 13, 2026 | Hawryluk P. Kent Indirect | Buy | $525.7K$525,662.70 |
Summary
Insiders reported 1 buys worth $525,662.70 and 7 sells worth $3.02M over the last 12 months. That adds up to net selling of $2.50M. Azoulay Salomon was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does MBX Biosciences, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MBX's management, answered from reported figures.
Who manages MBX?
MBX Biosciences, Inc. Common Stock (MBX) lists 12 active executives. The top listed executive is Jeffrey Held, Chief Legal Officer.
Are MBX insiders buying or selling?
Recent insider activity shows net buying of $215.80M.
Continue the stock analysis
Jump to another research area for this company.